TARA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Protara Therapeutics Inc (TARA) is not a strong buy for a beginner, long-term investor at this time. While there is potential upside based on analyst ratings and the company's pipeline, the lack of significant trading signals, weak financial performance, and neutral trading sentiment suggest holding off for now.
The MACD is slightly positive at 0.0445, indicating mild bullish momentum, but the RSI at 48.931 is neutral, showing no strong trend. Moving averages are converging, and the stock is trading near its pivot point of 5.159 with limited price movement expected in the short term.
JPMorgan's Overweight rating with a $27 price target highlights confidence in the company's pipeline, particularly TARA-002, which is considered de-risked due to its similarity to an approved drug in other markets.
No significant news or trading activity from insiders, hedge funds, or Congress. Financial performance remains weak, with no revenue growth and negative EPS. The stock's historical performance and technical indicators do not suggest a strong upward trend.
In Q4 2025, revenue remained at 0 with no growth. Net income improved by 35.54% YoY but remains negative at -$17.31 million. EPS dropped by 19.15% YoY to -0.38. Gross margin remains at 0, indicating no profitability.
JPMorgan initiated coverage with an Overweight rating and a $27 price target, citing confidence in the company's pipeline and its de-risked nature due to clinical experience with a similar drug.
